|
2026 Conference Publication Interim results of a randomized controlled practice change trial: Comparing diet, exercise, and internet-delivered cognitive behavioral therapy intervention in disorders of gut-brain interactionHoltmann, Gerald, Kulin, Dmitrii, Shah, Ayesha, Fairlie, Thomas, Koloski, Natasha and Jones, Michael (2026). Interim results of a randomized controlled practice change trial: Comparing diet, exercise, and internet-delivered cognitive behavioral therapy intervention in disorders of gut-brain interaction. HOBOKEN: WILEY. |
|
2026 Conference Publication Development and validation of GI symptoms animated pictograms (GAPs) as a diagnostic tool for gi dysfunction among patients with cognitive impairmentEhab Samir Ayad, Mina, Yeh Lee, Yeong, Holtmann, Gerald, Kuo, Braden, Schmulson, Max, Viet Hang, Dao, Ghoshal, Uday, Marie Lawenko, Rona, Miftahussurur, Muhammad, Ali, Enaam, Faizal, Mohd, Kueh, Erica and Oshima, Tadayuki (2026). IDDF2026-ABS-0193 Development and validation of GI symptoms animated pictograms (GAPs) as a diagnostic tool for gi dysfunction among patients with cognitive impairment. BMJ Publishing Group Ltd and British Society of Gastroenterology. doi: 10.1136/gutjnl-2026-iddf.271 |
|
2026 Conference Publication SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/ 2 DOSE ESCALATION AND OPTIMIZATION TRIALMa, Christopher, Nguyen, Nam Q., Ko, Hin Hin, Ho, Vincent, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Dobek, Christine, Dye, Andrew, Kowalski, Mark M. and Malone, Amanda (2026). SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/ 2 DOSE ESCALATION AND OPTIMIZATION TRIAL. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC. |
|
2026 Conference Publication A comparison of diagnostic methodologies for small intestinal bacterial overgrowth: aspirate culture, breath testing and the Atmo capsuleShah, Ayesha, Ghoshal, Uday C., Fairlie, Thomas, Ghoshal, Ujjala, Koloski, Natasha, Lim, Yenkai, Morrison, Mark, Sahu, Shikha, Singh, Madhuri, Spencer, Sean, Gibson, Peter R. and Holtmann, Gerald (2026). A comparison of diagnostic methodologies for small intestinal bacterial overgrowth: aspirate culture, breath testing and the Atmo capsule. Digestive Disease Week (DDW) 2026, Chicago, IL, United States, 2-5 May 2026. Philadelphia, PA, United States: Elsevier. doi: 10.1016/s0016-5085(26)05815-4 |
|
2026 Conference Publication Tu1102 Single administration of EP-104GI in resolve, a phase 1B/2 trial in eosinophilic esophagitis, improves endoscopic features of inflammation and fibrosis over 36 weeksGonsalves, Nirmala, Nguyen, Nam Q., Ko, Hin Hin, Ho, Vincent, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Ravikumar, Pranali, Dye, Andrew, Malone, Amanda and Kowalski, Mark M. (2026). Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKS. Gastrointestinal Endoscopy, 103 (5), S-817. doi: 10.1016/s0016-5107(26)02133-4 |
|
2026 Conference Publication 400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIALMa, Christopher, Nguyen, Nam Q., Ko, Hin Hin, Ho, Vincent, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Dobek, Christine, Dye, Andrew, Kowalski, Mark M. and Malone, Amanda (2026). 400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL. Elsevier BV. doi: 10.1016/s0016-5085(26)01797-x |
|
2026 Conference Publication Addiction medicine involvement is associated with improved hepatitis C and viral hepatitis screening among hospitalised incarcerated patients who inject drugsFraz, Ezaam, Kasas, Leda, Carter, Matthew, Yeo, Jeremy, Anandan, Aathavan Shanmuga, Connor, Jason, Playford, Geoffrey, Runnegar, Naomi, Hayllar, Jeremy, Holtmann, Gerald, Clark, Paul and Palmer, Andrew (2026). Addiction medicine involvement is associated with improved hepatitis C and viral hepatitis screening among hospitalised incarcerated patients who inject drugs. EASL Congress 2026, Barcelona, Spain, 27-30 May 2026. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s0168-8278(26)02216-6 |
|
2026 Conference Publication Sa1759 DISORDERS OF GUT-BRAIN INTERACTION PRESENTING WITH SEVERELY ALTERED FOOD INTAKE BEHAVIOR (DGBI-AFIB): CHARACTERISATION OF A DISTINCT PATIENT GROUPShah, Ayesha, Moy, Naomi, Kulin, Dmitrii, Callaghan, Gavin, Fairlie, Thomas, Virgo, Kate, Hansen, Teressa J., Jones, Michael P., Koloski, Natasha A., Thapar, Nikhil and Holtmann, Gerald (2026). Sa1759 DISORDERS OF GUT-BRAIN INTERACTION PRESENTING WITH SEVERELY ALTERED FOOD INTAKE BEHAVIOR (DGBI-AFIB): CHARACTERISATION OF A DISTINCT PATIENT GROUP. Elsevier BV. doi: 10.1016/s0016-5085(26)04460-4 |
|
2026 Conference Publication 400 Single administration of escalating doses of EP-104GI leads to persistent improvements in histological features of eosinophilic esophagitis over 36 weeks in resolve, a phase 1B/2 dose escalation and optimization trialMa, Christopher, Nguyen, Nam Q., Ko, Hin Hin, Ho, Vincent, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Dobek, Christine, Dye, Andrew, Kowalski, Mark M. and Malone, Amanda (2026). 400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL. Gastrointestinal Endoscopy, 103 (5), S-627. doi: 10.1016/s0016-5107(26)01728-1 |
|
2026 Conference Publication Prevalence of orthostatic intolerance in patients with disorders of gut-brain interaction: a systematic review and meta-analysisAyaki, Kana, Shah, Ayesha, Fairlie, Thomas, Kulin, Dmitrii, Staller, Kyle, Nurko, Samuel, Keefer, Laurie, Aziz, Qasim, Drossman, Douglas A., Jones, Michael P. and Holtmann, Gerald (2026). Tu1700 PREVALENCE OF ORTHOSTATIC INTOLERANCE IN PATIENTS WITH DISORDERS OF GUT-BRAIN INTERACTION: A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastrointestinal Endoscopy, 103 (5), S-1961. doi: 10.1016/s0016-5107(26)04630-4 |
|
2026 Conference Publication A comparison of diagnostic methodologies for small intestinal bacterial overgrowth: aspirate culture, breath testing and the Atmo capsuleShah, Ayesha, Ghoshal, Uday C., Fairlie, Thomas, Ghoshal, Ujjala, Koloski, Natasha, Lim, Yenkai, Morrison, Mark, Sahu, Shikha, Singh, Madhuri, Spencer, Sean, Gibson, Peter R. and Holtmann, Gerald (2026). Su1303 A COMPARISON OF DIAGNOSTIC METHODOLOGIES FOR SMALL INTESTINAL BACTERIAL OVERGROWTH: ASPIRATE CULTURE, BREATH TESTING AND THE ATMO CAPSULE. Gastrointestinal Endoscopy, 103 (5), S-2458. doi: 10.1016/s0016-5107(26)05746-9 |
|
2026 Conference Publication Tu1101 Durability of dysphagia improvements following single administration of EP-104GI in participants with eosinophilic esophagitis during dose escalation in the resolve trialBredenoord, Albert J., Nguyen, Nam Q., Ho, Vincent, Ko, Hin Hin, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Kolisnik, Tyler, Dye, Andrew, Malone, Amanda and Kowalski, Mark M. (2026). Tu1101 DURABILITY OF DYSPHAGIA IMPROVEMENTS FOLLOWING SINGLE ADMINISTRATION OF EP-104GI IN PARTICIPANTS WITH EOSINOPHILIC ESOPHAGITIS DURING DOSE ESCALATION IN THE RESOLVE TRIAL. Gastrointestinal Endoscopy, 103 (5), S-817. doi: 10.1016/s0016-5107(26)02132-2 |
|
2026 Conference Publication Comparison of culture of duodenal aspirate, glucose breath test and gas-sensing capsule data on the symptomatic response to rifaximin in patients with DGBIShah, Ayesha, Ghoshal, Uday C., Fairlie, Thomas, Ghoshal, Ujjala, Koloski, Natasha, Lim, Yenkai, Morrison, Mark, Sahu, Shikha, Singh, Madhuri, Spencer, Sean, Gibson, Peter R. and Holtmann, Gerald (2026). Comparison of culture of duodenal aspirate, glucose breath test and gas-sensing capsule data on the symptomatic response to rifaximin in patients with DGBI. Digestive Disease Week (DDW), Chicag, IL, United States, 2-5 May 2026. Philadelphia, PA, United States: Elsevier. |
|
2026 Conference Publication Acute effects of botulinum toxin on the distensibility of the LES in patients with suspected achalasia and esophageal outlet obstructionLuong, Suzanna, Wang, William J., McKillen, Ben, Moy, Naomi, Do, Anh and Holtmann, Gerald (2026). Acute effects of botulinum toxin on the distensibility of the LES in patients with suspected achalasia and esophageal outlet obstruction. Digestive Disease Week (DDW) 2026, Chicago, IL, United States, 2-5 May 2026. Philadelphia, PA, United States: Elsevier. doi: 10.1016/s0016-5085(26)01999-2 |
|
2026 Conference Publication Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKSGonsalves, Nirmala, Nguyen, Nam Q., Ko, Hin Hin, Ho, Vincent, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Ravikumar, Pranali, Dye, Andrew, Malone, Amanda and Kowalski, Mark M. (2026). Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKS. Elsevier BV. doi: 10.1016/s0016-5085(26)02202-x |
|
2026 Conference Publication Tu1669 CHRONIC GASTROINTESTINAL SYMPTOMS AND SYSTEMIC COMORBIDITIES IN ADULT PATIENTS WITH HYPERMOBILITY SPECTRUM DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSISKulin, Dmitrii, Shah, Ayesha, Fairlie, Thomas, Staller, Kyle, Nurko, Samuel, Keefer, Laurie, Aziz, Qasim, Drossman, Douglas A., Jones, Michael P. and Holtmann, Gerald (2026). Tu1669 CHRONIC GASTROINTESTINAL SYMPTOMS AND SYSTEMIC COMORBIDITIES IN ADULT PATIENTS WITH HYPERMOBILITY SPECTRUM DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Elsevier BV. doi: 10.1016/s0016-5085(26)04668-8 |
|
2026 Conference Publication IRRITABLE BOWEL SYNDROME IS ASSOCIATED WITH A 2.5-FOLD INCREASED RISK OF INFERTILITY AMONG PRIMARY CARE PATIENTSKoloski, Natasha A., Jones, Michael P., Shah, Ayesha, Holtmann, Gerald and Talley, Nicholas J. (2026). IRRITABLE BOWEL SYNDROME IS ASSOCIATED WITH A 2.5-FOLD INCREASED RISK OF INFERTILITY AMONG PRIMARY CARE PATIENTS. Digestive Disease Week (DDW), Chicago Il, May 02-05, 2026. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC. |
|
2026 Conference Publication 582 COMPARISON OF CULTURE OF DUODENAL ASPIRATE, GLUCOSE BREATH TEST AND GAS-SENSING CAPSULE DATA ON THE SYMPTOMATIC RESPONSE TO RIFAXIMIN IN PATIENTS WITH DGBIShah, Ayesha, Ghoshal, Uday C., Fairlie, Thomas, Ghoshal, Ujjala, Koloski, Natasha, Lim, Yenkai, Morrison, Mark, Sahu, Shikha, Singh, Madhuri, Spencer, Sean, Gibson, Peter R. and Holtmann, Gerald (2026). 582 COMPARISON OF CULTURE OF DUODENAL ASPIRATE, GLUCOSE BREATH TEST AND GAS-SENSING CAPSULE DATA ON THE SYMPTOMATIC RESPONSE TO RIFAXIMIN IN PATIENTS WITH DGBI. Elsevier BV. doi: 10.1016/s0016-5085(26)05702-1 |
|
2026 Conference Publication Su1302 In vitro effects of rifaximin on the duodenal mucosa associated microbiota cultured from patients with overlapping disorders of gut-brain interactionFairlie, Thomas, Celine, Patricia, Shah, Ayesha, Lim, Yenkai, Morrison, Mark and Holtmann, Gerald (2026). Su1302 IN VITRO EFFECTS OF RIFAXIMIN ON THE DUODENAL MUCOSA ASSOCIATED MICROBIOTA CULTURED FROM PATIENTS WITH OVERLAPPING DISORDERS OF GUT-BRAIN INTERACTION. Gastrointestinal Endoscopy, 103 (5), S-2457. doi: 10.1016/s0016-5107(26)05745-7 |
|
2026 Conference Publication Irritable bowel syndrome is associated with a 2.5-fold increased risk of infertility among primary care patientsKoloski, Natasha A., Jones, Michael P., Shah, Ayesha, Holtmann, Gerald and Talley, Nicholas J. (2026). Su1764 IRRITABLE BOWEL SYNDROME IS ASSOCIATED WITH A 2.5-FOLD INCREASED RISK OF INFERTILITY AMONG PRIMARY CARE PATIENTS. Gastrointestinal Endoscopy, 103 (5), S-1887. doi: 10.1016/s0016-5107(26)04468-8 |
